Bullboard - Stock Discussion Forum Johnson and Johnson JNJ

Healthcare Drug Manufacturers - Major

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory... see more

Add To Watchlist

Bullboard (NYSE:JNJ)

View:

(0)
•••

Post by PressReleaseon Jul 08, 2025 8:00am

New Press Release - Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo

Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placeboCAPLYTA® is FDA approved to treat schizophrenia and is the first and only approved treatment for bipolar I and II depression as an adjunctive and...read article.

(0)
•••

Post by PressReleaseon Jun 23, 2025 7:32am

New Press Release - IMAAVY(TM) (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMGIMAAVY, an FcRn blocker, received U.S. FDA approval earlier this year...read article.

(0)
•••

Post by PressReleaseon Jun 15, 2025 3:15am

New Press Release - Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMAData signal potential of novel, off-the-shelf approach in patients with extramedullary disease who face significant unmet needsMILAN, June 15...read article.

(0)
•••

Post by PressReleaseon Jun 13, 2025 11:00am

New Press Release - Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease75-80% complete response rate among evaluable patients at the recommended Phase 2 dose MILAN, June 13, 2025 /PRNewswire...read article.

(0)
•••

Post by PressReleaseon Jun 12, 2025 11:00am

New Press Release - New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia

Bleximenib, an investigational selective menin inhibitor, shows potential as combination therapy for the treatment of relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML Phase 1b data show low rate of differentiation syndrome and no cardiac safety signal of QTc...read article.

(0)
•••

Post by PressReleaseon Jun 11, 2025 8:05am

New Press Release - New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

TREMFYA ® demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo in the Phase 3b APEX studyMore than 40% of TREMFYA®-treated patients across both dose groups achieved ACR50 at Week 24Improvement in both joint and skin symptoms reinforce TREMFYA® as a...read article.

(0)
•••

Post by PressReleaseon Jun 10, 2025 4:52pm

New Press Release - Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ “We are thrilled to have Daniel join...read article.

(0)
•••

Post by PressReleaseon Jun 03, 2025 10:45am

New Press Release - Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI® remain progression-free CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatmentCHICAGO, June 3, 2025 /PRNewswire...read article.

(0)
•••

Post by PressReleaseon Jun 03, 2025 10:45am

New Press Release - Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients

Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myelomaNovel investigational dual-antigen-targeting immunotherapy binds to B-cell maturation antigen (BCMA) and GPRC5D on myeloma cells, as well as CD3 on T-cells CHICAGO,...read article.

(0)
•••

Post by PressReleaseon Jun 03, 2025 10:45am

New Press Release - DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity

More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO® for 24 months or longer in the Phase 3 PERSEUS studyData from Phase 3 CEPHEUS study show 60 percent overall MRD negativity (10−5) and improved PFS with DARZALEX FASPRO® in transplant...read article.

(0)
•••

Post by PressReleaseon Jun 03, 2025 8:00am

New Press Release - Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC

Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptomsData show a nearly 50 percent reduction in disease progression in BRCA-altered mCSPC vs. current standard of...read article.

(0)
•••

Post by PressReleaseon May 28, 2025 4:43pm

New Press Release - Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16thto review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren...read article.

(0)
•••

Post by PressReleaseon May 21, 2025 4:40pm

New Press Release - Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference

Johnson & Johnson (NYSE: JNJ) will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 9:00 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson’s...read article.

(0)
•••

Post by PressReleaseon May 20, 2025 6:22pm

New Press Release - U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA studyIf approved, DARZALEX FASPRO® would be the first treatment to potentially delay or prevent progression to multiple myelomaRARITAN, N.J., May 20, 2025 /PRNewswire/ -- Johnson...read article.

(0)
•••

Post by PressReleaseon May 14, 2025 4:40pm

New Press Release - Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th, 2025. Management will participate in a Fireside Chat at 3:20 p.m. Eastern Time. This live audio webcast will be available to investors and other interested...read article.

Market Update

A daily snapshot of everything
from market open to close.

Become a member today, It's free!

Bullboard - Stock Discussion Forum Johnson and Johnson JNJ

Bullboard (NYSE:JNJ)

New Press Release - Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo

New Press Release - IMAAVY(TM) (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)

New Press Release - Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

New Press Release - Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

New Press Release - New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia

New Press Release - New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

New Press Release - Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

New Press Release - Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

New Press Release - Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients

New Press Release - DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity

New Press Release - Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC

New Press Release - Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

New Press Release - Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference

New Press Release - U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

New Press Release - Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Featured News Links

A different approach to mineral exploration and development — scale, diversification & optionality

Additional government funding secured to advance construction of hydrocarbon condensate refinery

AI Wellness Stock Targeting Massive Growth (CSE: ALEN.U)

New Gold Opportunities in the Cariboo Region (CSE:GCC) (OTC:GCCFF)

Cannabis Investors Are Watching Herbal Dispatch (CSE:HERB)

Sekur Private Data CEO Updates on Growth, Market Expansion, Corporate Developments and New Product Launch

Cielo Executes LOI to Advance Clean Fuels Project Development Through Strategic Asset Acquisition

Podcasts

Become a member today, It's free!

Sign In

Send my password

Become a member today, It's free!

Bullboard - Stock Discussion Forum Johnson and Johnson JNJ

Join the community and start posting on the bullboards today. It's free.

Create a portfolio watchlist today. It's free.

Bullboard (NYSE:JNJ)

Featured News Links

Podcasts